6-K ·Filed Oct 16, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Monitor for topline data in Q1 2027, which is the next binary catalyst. No financial or operational changes in this filing.
Latest settled — T+5d ⚠ clustered
TLSA ▼ -4.76% at T+5d
NEUTRAL call -4.76% · α vs SPY -4.85% · entry $1.05 → $1.00
T+1d
-3.81%
call -3.81% · α -4.23%
$1.01
settled 7d ago
T+5d
-4.76%
call -4.76% · α -4.85%
$1.00
settled 3d ago
T+20d
Pending
in 18d
T+60d
Pending
in 3mo
Price Chart
Loading chart...
Executive Summary
Tiziana Life Sciences announced that the last patient has begun dosing in its Phase 2 trial of intranasal foralumab for early/mild Alzheimer's disease. Topline data are expected in Q1 2027. This is a routine operational milestone for a clinical-stage biotech with no financial data or binary catalyst in the filing.
Key Facts
- Last patient began dosing in Phase 2 randomized, placebo-controlled trial of intranasal foralumab for early/mild Alzheimer's disease
- Topline data anticipated in Q1 2027
- Trial evaluates intranasal foralumab as monotherapy and in combination with lecanemab or donanemab
- Key endpoints include TSPO-PET imaging, cognitive function, and fluid biomarkers
Financial Impact
No financial figures reported in the filing
Risk Factors
- Phase 2 data may fail to meet endpoints
- No guarantee of positive results
- Competition from approved anti-amyloid therapies
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-110008 |
| Document: ea030884501ex99-1.htm | 0001213900-26-110008 |
| Document: 0001213900-26-110008-index-headers.html | 0001213900-26-110008 |
| Document: 0001213900-26-110008-index.html | 0001213900-26-110008 |
| Document: 0001213900-26-110008.txt | 0001213900-26-110008 |
25 reports for TLSA
54% Hit rate @ T+20 Went positive at some point 13 of 15 best @ T+20▲ +19.82%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (−11.81%) |
Oct 16, 2026 9d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (+11.81%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8907 (−15.17%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8907 (−19.76%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8907 (−9.11%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8907 (−1.54%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8907 (−22.55%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8907 (−8.18%) |
Showing 10 of 25
US Market Status
Market Open — Closes in 4h 42m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers